AbbVie and Google's Calico strike $1.5bn age-related drug deal
This article was originally published in Scrip
AbbVie and Google's mysterious life sciences company Calico announced a plan to co-invest up to $1.5bn in a research collaboration to develop new therapies that treat age-related diseases, including neurodegeneration and cancer.
You may also be interested in...
Scrip begins its week at the BIO International Convention with interviews and panel discussions about dealmaking and progressing development pipelines. Among the first day highlights: Janssen's hunt for technology, Boehringer's NASH plans and rising investment in neuroscience.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.